Massively overpaid XLT for what they bring to the table to help Emil succeed. They have utterly failed him and spent colossal amounts of money hiring employees in manufacturing, building facilities, hiring ridiculous roles in quality/compliance to manage minimal risk at external CMOs. The one internal site they built, they failed the pre-approval inspection with a CRL from the FDA resulting in a 31 percent decline in stock price on Monday.
The stock was deeply diluted since 2021 from approx. 60 million shares outstanding to 100 million shares while price tanked from 75/100 per share to 27/share resulting in destruction of market cap from 5/6 billion to 2.5 billion in 4 short years while losing money every year and accumulating billions of losses and paying the executives massive amounts of salaries, bonuses and options. Since it went public in 2014 and closed at 44/share, with four approved products, 11 years later it is at 27. The board has to investigate this gross negligence and mismanagement of the company and using the company like a piggy bank with accountability.